siRNA-directed inhibition of HIV-1 infection

By C. Novina, M. Murray, D. Dykxhoorn, P. Beresford, J. Riess, Sang-Kyung Lee, Ronald G. Collman, J. Lieberman, P. Shankar, Phillip A. Sharp. Nature Medicine, 2002

743 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Non‐coding RNAs: regulators of disease (2010, background): “Hopes for RNA-based and RNA-targeted therapies were bolstered by early successes using siRNAs in human in vitro culture systems [206] and in targeting HIV-1 and human BCL2 with siRNA-like molecules [207–209].”
Stable suppression of tumorigenicity by virus-mediated RNA interference. (2002, background): “It was shown recently that RNA viruses are sensitive to RNA interference (Gitlin et al., 2002; Jacque et al., 2002; Novina et al., 2002).”
RNAi therapeutics: principles, prospects and challenges. (2007, methodology): “Cellular cofactors, such as NFκβ [93], the HIV receptor CD4 [94] and co-receptors CXCR4 and CCR5 [96] have also been successfully downregulated by RNAi resulting in an inhibition of HIV replication.”
Lentivirus-delivered stable gene silencing by RNAi in primary cells. (2003, background): “Primary cells have been shown to possess the machinery to silence gene expression using siRNA (McCaffrey et al. 2002; Novina et al. 2002).”
Gene silencing in mammals by small interfering RNAs (2002, background): “By contrast, siRNAs that target the ORF of human CD4 are effectiv”